Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.871
-0.013 (-1.47%)
Apr 29, 2026, 12:42 PM EDT - Market open
Longeveron Employees
Longeveron had 38 employees as of December 31, 2025. The number of employees increased by 12 or 46.15% compared to the previous year.
Employees
38
Change (1Y)
12
Growth (1Y)
46.15%
Revenue / Employee
$31,553
Profits / Employee
-$597,474
Market Cap
25.51M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Jasper Therapeutics | 22 |
| ABVC BioPharma | 19 |
| NeuroSense Therapeutics | 17 |
| Quantum BioPharma | 17 |
| Lantern Pharma | 16 |
| Barinthus Biotherapeutics | 14 |
| AEON Biopharma | 8 |
| Neuphoria Therapeutics | 8 |
LGVN News
- 21 days ago - Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - GlobeNewsWire
- 6 weeks ago - Longeveron Earnings Call Transcript: Q4 2025 - Transcripts
- 6 weeks ago - Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Longeveron Braces For Q4 Results Following Recent Funding Boost - Benzinga
- 6 weeks ago - Longeveron Announces Closing of Private Placement of up to $30 Million - GlobeNewsWire
- 7 weeks ago - Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal - Benzinga
- 2 months ago - Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - GlobeNewsWire
- 2 months ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire